Protocol Number: 99-C-0044

Title:

Immunization of Patients with Metastatic Melanoma Using a Recombinant RF-GP100P209 Virus Encoding a gp100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Number:

99-C-0044

Summary:

Patients with metastatic melanoma who are HLA-A201+ will be immunized with recombinant fowlpox virus encoding a modified peptide from the gp100 molecule preceded by a signal sequence designed to improve peptide presentation by antigen presenting cells. This virus will be administered either intramuscularly or intravenously. Patients will be evaluated for clinical response, as well as undergo studies of the immunologic response to the virus immunization.

Sponsoring Institute:

National Cancer Institute (NCI)

Recruitment Detail

Type: Follow-up Of Previously Enrolled Subjects Only

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): None

Eligibility Criteria: This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Special Instructions: Currently Not Provided

Disease Category:

PROTICD

Keywords:

Vaccine

IL-2

Phase II

HLA-A201+

Melanoma Antigen

Recruitment Keywords:

None

Conditions:

Melanoma

Neoplasm Metastasis

Investigational Drug(s):

IL-2

Fowlpox gp100:209-217 (210 M)

Investigational Device(s):

None

Contacts:

This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Citations:

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating intotumor

Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans

Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/16/2004